Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: The SYNERGY trial

American Heart Journal

Volumn 149, Issue 4 SUPPL., 2005, Pages

  Mahaffey, Kenneth W ^a   Ferguson, James J ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; ENOXAPARIN; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ECG ABNORMALITY; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST ELEVATION ACUTE CORONARY SYNDROME; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ST SEGMENT; STATISTICAL SIGNIFICANCE;

EID: 17544383843     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.02.023     Document Type: Article

References (27)

1. M. Cohen, C. Demers, and E.P. Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group N Engl J Med 337 1997 447 452
2. E.M. Antman, C.H. McCabe, and E.P. Gurfinkel Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial Circulation 100 1999 1593 1601
3. E.M. Antman, M. Cohen, and D. Radley Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis Circulation 100 1999 1602 1608
4. E.M. Antman, M. Cohen, and C. McCabe Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE Eur Heart J 23 2002 308 314
5. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
6. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
7. The EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Lancet 352 1998 87 92
8. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Lancet 356 2000 2037 2044
9. The PRISM-PLUS Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction N Engl J Med 338 1998 1488 1497
10. The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes N Engl J Med 339 1998 436 443
11. E. Karvouni, D.G. Katritsis, and J.P. Ioannidis Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J Am Coll Cardiol 41 2003 26 32
12. D.F. Kong, V. Hasselblad, and R.A. Harrington Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions Am J Cardiol 92 2003 651 655
13. E. Boersma, R.A. Harrington, and D.J. Moliterno Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 359 2002 189 198
14. M. Roffi, D.P. Chew, and D. Mukherjee Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy Eur Heart J 23 2002 1441 1448
15. M.S. Sabatine, D.A. Morrow, and R.P. Giugliano Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: A comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 Trial Circulation 109 2004 874 880
16. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators Lancet 354 1999 708 715
17. C.P. Cannon, W.S. Weintraub, and L.A. Demopoulos Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 344 2001 1879 1887
18. K.A. Fox, P.A. Poole-Wilson, and R.A. Henderson Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina Lancet 360 2002 743 751
19. M.A. Blazing, J.A. De Lemos, and C.K. Dyke The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy Am Heart J 142 2001 211 217
20. D.J. Kereiakes, C. Grines, and E. Fry Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention J Invasive Cardiol 13 2001 272 278
21. J.J. Ferguson, E.M. Antman, and E.R. Bates Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study Am Heart J 146 2003 628 634
22. S.G. Goodman, D. Fitchett, and P.W. Armstrong Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide Circulation 107 2003 238 244
23. S.R. Tunis, D.B. Stryer, and C.M. Clancy Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy JAMA 290 2003 1624 1632
24. The SYNERGY Trial Investigators Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
25. The SYNERGY Executive Committee The SYNERGY trial: study design and rationale Am Heart J 143 2002 952 960
26. A.K. Rao, C. Pratt, and A. Berke Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11
27. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682